Vivos Therapeutics Q3 revenue rises on service segment growth
VVOS•Vivos Therapeutics’ third-quarter revenue rose 24% quarter over quarter, driven by higher service revenue. Its operating loss improved 18% year over year, while gross margin fell to 52% from 58%.
1. Revenue and costs
Vivos Therapeutics reported a 24% quarter-over-quarter increase in third-quarter revenue, driven by higher service revenue. Service revenue rose slightly as product revenue declined, reflecting a shift away from appliance sales to dentists in the VIP program.
2. Loss and margin
The operating loss improved 18% year over year to $3.90 million, with lower general and administrative and sales and marketing expenses. Gross margin fell to 52% from 58% a year earlier, mainly due to lower product revenue and higher cost of sales; net loss was $1.97 million and loss per share was $0.07.
3. Outlook and compliance
The company expects new clinical initiatives to contribute to revenue and margins starting in the fourth quarter of 2026. It also expects payer contract renegotiations and ongoing cost reductions to support growth and efficiencies, and said it regained compliance with Nasdaq’s stockholders’ equity requirement after the SOD Sciences transaction.




